
India’s Pharmaceutical Quality Issues Could Soon Extend to Generic Versions of Ozempic
Last year, Americans spent more than $15 billion on Novo Nordisk’s diabetes and weight-loss drugs Ozempic and Wegovy. The active ingredient in both treatments — semaglutide— has rapidly become one of the world’s most commercially successful medicines.





